Valproic acid (VPA) reduces latent human immunodeficiency virus (HIV) reservoirs by activating resting CD4+ cells. This retrospective case-control study (n = 30) examined effects of VPA on markers of HIV progression. VPA was not associated with changes in cerebrospinal fluid viral loads (VL), plasma VL, or neuropsychological performance. VPA patients had a trend towards lower CD4+ cells (P = .08) at follow-up. Concurrent antiretrovirals did not alter these relationships. VPA does not induce viremia or promote disease progression and may be safe for clinical intervention.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/13550280600981695 | DOI Listing |
Publication Analysis
Top Keywords
valproic acid
8
human immunodeficiency
8
immunodeficiency virus
8
disease progression
8
cd4+ cells
8
vpa
5
acid affect
4
affect markers
4
markers human
4
virus disease
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!